Tandem autologous stem cell transplantation in elderly patients with myeloma: A multicenter retrospective analysis-Reference-Cited by-同舟云学术

Tandem autologous stem cell transplantation in elderly patients with myeloma: A multicenter retrospective analysis

Published:2023-01-17 Issue:4 Volume:110 Page:444-454
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Suzuki Kazuhito¹²^ORCID,Mizuno Shohei³,Shimazu Yutaka⁴,Fuchida Shin‐ichi⁵,Hagiwara Shotaro⁶,Itagaki Mitsuhiro⁷,Nishiwaki Kaichi¹²,Hangaishi Akira⁸,Karasuno Takahiro⁹,Kikuchi Taku¹⁰,Shimizu Misayo¹¹,Nishikawa Akinori¹²,Kobayashi Takeshi¹³,Sunami Kazutaka¹⁴,Hiramoto Nobuhiro¹⁵,Uchiyama Hitoji¹⁶,Maruyama Yumiko¹⁷,Kanda Yoshinobu¹⁸,Ichinohe Tatsuo¹⁹,Atsuta Yoshiko²⁰²¹,Yano Shingo²,Kawamura Koji²², ,

Affiliation:

1. Division of Clinical Oncology/Hematology, Department of Internal Medicine The Jikei University Kashiwa Hospital Kashiwa Japan

2. Division of Clinical Oncology/Hematology, Department of Internal Medicine The Jikei University School of Medicine Kashiwa Japan

3. Division of Hematology, Department of Internal Medicine Aichi Medical University Nagakute Japan

4. Department of Hematology and Oncology, Graduate School of Medicine Kyoto University Kyoto Japan

5. Department of Hematology Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center Kyoto Japan

6. Division of Hematology Tsukuba University Hospital Mito Clinical Education and Training Center Tsukuba Japan

7. Department of Hematology Hiroshima Red Cross Hospital & Atomic‐Bomb Survivors Hospital Hiroshima Japan

8. Department of Hematology National Center for Global Health and Medicine Tokyo Japan

9. Division of Hematology Rinku General Medical Center Izumisano Japan

10. Division of Hematology, Department of Medicine Keio University School of Medicine Tokyo Japan

11. Department of Hematology and Oncology Hitachi, Ltd. Hitachi General Hospital Hitachi Japan

12. Department of Hematology/Oncology Wakayama Medical University Wakayama Japan

13. Hematology Division Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital Tokyo Japan

14. Department of Hematology National Hospital Organization Okayama Medical Center Okayama Japan

15. Department of Hematology Kobe City Medical Center General Hospital Kobe Japan

16. Department of Hematology Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan

17. Department of Hematology University of Tsukuba Hospital Tsukuba Japan

18. Division of Hematology Jichi Medical University Shimotsuke Japan

19. Department of Hematology and Oncology Research Institute for Radiation Biology and Medicine, Hiroshima University Hiroshima Japan

20. Japanese Data Center for Hematopoietic Cell Transplantation Aichi Japan

21. Department of Registry Science for Transplant and Cellular Therapy Aichi Medical University School of Medicine Aichi Japan

22. Division of Clinical Laboratory Medicine, Department of Multidisciplinary Internal Medicine, Faculty of Medicine Tottori University Tottori Japan

Abstract

AbstractTandem autologous stem cell transplantation (ASCT) has been reconsidered for high‐risk patients with myeloma, and the eligibility criteria for up‐front ASCT have been updated to include more elderly patients. This study aimed to evaluate the efficacy and tolerability of tandem ASCT in elderly patients with myeloma compared to tandem ASCT in young patients and single ASCT in elderly patients. A retrospective study using the Transplant Registry Unified Management Program database of the Japanese Society for Transplantation and Cellular Therapy, which included 64 elderly and 613 young patients who received tandem ASCT, and 891 elderly patients who received single ASCT, was conducted. The median overall survival (OS) over 38.5 months in the elderly and young patients who received tandem ASCT, and elderly patients who received single ASCT was 78.9, 92.5, and 77.1 months, respectively; no significant difference in the median OS was observed. The cumulative incidence of transplantation‐related mortality was similar in the elderly and young patients receiving tandem ASCT. High‐risk cytogenetic abnormality was not identified as a poor prognostic factor for OS in elderly patients who received tandem ASCT but in those who received single ASCT. Thus, tandem ASCT was effective and tolerable in elderly patients with myeloma.

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13922

Reference37 articles.

1. Improved survival in multiple myeloma and the impact of novel therapies

2. Autologous Transplantation and Maintenance Therapy in Multiple Myeloma

3. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

4. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

5. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation;2023-11-17